{"id":"start-adalimumab-in-monotherapy","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Injection site reactions"},{"rate":"7-10%","effect":"Upper respiratory tract infections"},{"rate":"5-8%","effect":"Headache"},{"rate":"0.1-0.5%","effect":"Tuberculosis reactivation"},{"rate":"1-3%","effect":"Opportunistic infections"},{"rate":"increased relative risk","effect":"Malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in immune-mediated inflammatory diseases. By preventing TNF-α from binding to its receptors on immune cells, it suppresses the inflammatory cascade and reduces tissue damage. This mechanism is particularly effective in conditions driven by excessive TNF-α production, such as inflammatory bowel disease and rheumatoid arthritis.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:40.858Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT03306446","phase":"PHASE4","title":"Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2015-03-17","conditions":"CD","enrollment":203}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["begin humira in monotherapie in Early crohn disease patient"],"phase":"marketed","status":"active","brandName":"Start adalimumab in monotherapy","genericName":"Start adalimumab in monotherapy","companyName":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","companyId":"groupe-d-etude-therapeutique-des-affections-inflammatoires-digestives","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Crohn's disease, Ulcerative colitis, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}